About Ionetix
Ionetix is a company based in San Francisco (United States) founded in 2009.. Ionetix has raised $61.08 million across 3 funding rounds from investors including Lilly and Tees River. Ionetix offers products and services including N-13 Ammonia and Targeted Alpha Therapy. Ionetix operates in a competitive market with competitors including ImaginAb, Conavi, AC Immune, APRINOIA and Innovate Biopharma, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ionetix Corporation
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$61.08 M (USD)
in 3 rounds
-
Latest Funding Round
-
Investors
Lilly
& 1 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ionetix
Ionetix offers a comprehensive portfolio of products and services, including N-13 Ammonia and Targeted Alpha Therapy. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Radiopharmaceutical for cardiac PET imaging diagnostics.
Uses alpha radionuclides for targeted cancer therapy applications.
Unlock access to complete
Funding Insights of Ionetix
Ionetix has successfully raised a total of $61.08M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Last Round
-
First Round
First Round
(09 Mar 2018)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2024 | Amount | Series C - Ionetix | Valuation | Lilly | |
| May, 2020 | Amount | Series C - Ionetix | Valuation |
investors |
|
| Mar, 2018 | Amount | Series B - Ionetix | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ionetix
Ionetix has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Lilly and Tees River. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Traditional pharmaceutical medicines are developed for multiple health fields.
|
Founded Year | Domain | Location | |
|
Invests in sustainable returns from global economy's Net Zero transition for professional investors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ionetix
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ionetix
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ionetix Comparisons
Competitors of Ionetix
Ionetix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ImaginAb, Conavi, AC Immune, APRINOIA and Innovate Biopharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
|
|
| domain | founded_year | HQ Location |
Catheter-based ultrasound systems for cardiac imaging are developed.
|
|
| domain | founded_year | HQ Location |
Antibodies, small molecules, and vaccines are developed for neurodegenerative diseases.
|
|
| domain | founded_year | HQ Location |
Diagnostics and therapeutics for neurodegenerative disorders are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule drugs and imaging agent for GI disorders
|
|
| domain | founded_year | HQ Location |
Imaging compounds & targeted radiotherapies to detect and treat prostate cancer.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ionetix
Frequently Asked Questions about Ionetix
When was Ionetix founded?
Ionetix was founded in 2009 and raised its 1st funding round 9 years after it was founded.
Where is Ionetix located?
Ionetix is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Ionetix?
Kevin Cameron is the current CEO of Ionetix.
Is Ionetix a funded company?
Ionetix is a funded company, having raised a total of $61.08M across 3 funding rounds to date. The company's 1st funding round was a Series B of $23.8M, raised on Mar 09, 2018.
What does Ionetix do?
Ionetix Corporation was founded in 2009 and is headquartered in San Francisco, United States. Operations focus on the development of superconducting cyclotrons designed for on-site production of positron emission tomography (PET) radioisotopes. The ION-12 system automates the generation of N-13 ammonia, an FDA-approved radiopharmaceutical utilized in myocardial perfusion PET studies to detect coronary artery disease. This technology is applied within the medical imaging sector.
Who are the top competitors of Ionetix?
What products or services does Ionetix offer?
Ionetix offers N-13 Ammonia and Targeted Alpha Therapy.
Who are Ionetix's investors?
Ionetix has 2 investors. Key investors include Lilly, and Tees River.